Jazz Sues FDA Over Lumryz Approval

During the second quarter, Jazz Pharmaceuticals registered a 39% year-over-year growth in net product sales of its low-sodium Xywav.

Related Keywords

United States ,American ,Oxybate Xywav ,American Academy Of Neurology Annual Meeting ,Jazz Pharmaceuticals ,American Academy ,Neurology Annual Meeting ,Orphan Drug Exclusivity ,